Dosage Forms

Chris Spivey is the editorial director of 

Articles

Marcel Baumann, business development director at Recipharm, discusses soft mist inhaler technology from the show floor at the World Vaccine Conference.

Discussing Soft Mist Inhaler Technology with Marcel Baumann (World Vaccine Conference 2023)

SPX-001, a respiratory drug candidate, will be submitted through a combined Clinical Trial and Ethics Committee application for further advancement in the clinical stages. 

Next Step in Clinical Development of Respiratory Drug Candidate SPX-001 Confirmed

Lonza has joined IPAC-RS, providing benefits to Lonza’s inhalation- related businesses due to IPAC-RS’ global voice of the orally inhaled and nasal drug products industry.

Lonza Joins IPAC-RS, an International Consortium Advancing the Regulatory Science of Inhalation Products

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers as part of AstraZeneca’s Ambition Zero Carbon program. 

AstraZeneca Progresses Ambition Zero Carbon Program with Honeywell Partnership to Develop Next-Generation Respiratory Inhalers

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

CDMOs offer expertise and capacity for spray drying.

Spray Drying Finds Growing Use for ASDs

Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery. 

Considerations for DPIs and MDIs in Inhalation Drug Delivery

When designing and manufacturing a pMDI or DPI combination drug-delivery device, the commercial stage should be kept in mind from the beginning of development.  

Best Practices in Manufacturing Inhalation Drugs

Editor of Pharmaceutical Technology Europe

The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.

Getting a Nose for Vaccines

FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension. 

FDA Grants Orphan Drug Designation to Aerami Therapeutics’s Imatinib

Signal Rx Pharmaceuticals, Crystec, and ADYA Consulting are collaborating on the development of an inhaled dry powder formulation of SF2523 to treat pulmonary fibrosis, lung cancer, and SARS-CoV-2 related illnesses.